Pharmafile Logo

Launch excellence

- PMLiVE

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines today.

With a rapidly changing clinical, economic and regulatory environment, the launch of new products has catapulted the pharmaceutical industry into greater complexity and pressure than ever before. Historically, new asset launches have been a tale of two halves: a hit or miss. Between 2009 and 2017, 40% of worldwide drug launches failed to meet their 2-year sales forecasts, according to McKinsey & Company1. Taking into consideration the evolving environment, there has never been a greater need for new models to navigate the path of an asset to market.

Over the past 15 years, our clients have regularly come to us to help them execute their launch plans. Often the ask is around launch readiness and activation, with a focus on tactical execution. In this article, we discuss the need to get ahead of tactical planning and demonstrate the role of ‘pre-launch asset preparedness’, to ensure we maximise the potential of specialised medicines in this highly complex environment.

You can read the full article online here or download it so you can read it later here.

If you’re planning a launch and looking for some advice, get in touch! We’re hosting free launch-strategy clinics throughout May and June. Contact Cheryl Harrison Doyle or Clare Reynolds for more details.

cheryl.harrisondoyle@wearelucidgroup.com
07818 568882

clare.reynolds@wearelucidgroup.com
07501 989799

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Cultivating a learner-led culture: agile learning and the growth mindset

In this month’s Smart Thinking blog on PM.Live.com, Michelle Sweet, Learning and Development Consultant at Lucid Group, discusses the needs for a learner-led culture and a growth mindset in the...

Bluedog expands into the US with the appointment of George Pearson as Client Solutions Director

Bluedog, a Lucid Group Company, has elevated and expanded its creative team into the US with the appointment of George Pearson as Client Solutions Director.George is a highly experienced medical...

The inescapable rise of patient-centricity

The April issue of PME questions the meaning of ‘patient-centricity’ and whether we are achieving it.Patient-centricity has become a ubiquitous value within the pharmaceutical industry; however, is pharma delivering on...

Vivid welcomes magical new talent to the team

Vivid Medical Communications, a Lucid Group company, is delighted to announce two magical additions to the team.Deborah Blain joins Vivid as an Account Manager. With over 10 years’ experience in...

Easter Magic for Lucid Group

Lucid’s Futures Executives were set the challenge of planning a magical Easter surprise across its seven offices. After an egg-citing (sorry!) brainstorm the grads chose three activities.-    Egg-cellent Easter egg hunt-    You’re...

Lucid Group announces the appointment of new CFO

Lucid Group continues to build its infrastructure in line with its ambitious growth plans by appointing Michael Joyce as Chief Financial Officer (CFO).Michael has considerable experience as a CFO and...

Lucid Group Launch a Pioneering Leadership Programme for its Business Leaders

Great companies start with great leaders. However effective leadership requires skill, emotional intelligence, and most importantly, on-going self-improvement.With this in mind, Lucid Group has launched a new leadership programme for...

Leading Edge, a Lucid Group company, strengthens its senior client services team

Leading Edge, a Lucid Group company, is delighted to announce the appointment of its new Lead Client Partnership Director, Frances O’Connor.Frances is an experienced strategic healthcare communicator with expertise in...

From Cowgirl to Medical Writer – How did that happen?

Amy Jackson, Editorial Director, Lucid Group discusses her unlikely path into Medical Communications.

Measures for measures

Why pharma’s marketing metrics must close the loop